🧬 Genetic Disorder

Klippel-Trenaunay Syndrome

Also known as: KTS, Angio-osteohypertrophy syndrome, Klippel-Trenaunay-Weber Syndrome

Klippel-Trenaunay Syndrome (KTS) is a rare congenital vascular disorder characterized by the triad of port-wine stain (capillary malformation), varicose veins, and bony and soft tissue hypertrophy, typically affecting one or more limbs. The severity of symptoms varies widely among affected individuals. While the exact cause is unknown, it is thought to be due to sporadic genetic mutations occurring during embryonic development.

👥 1 in 100,000 Prevalence
🔬 15 Active Trials

Imagine some of your blood vessels and bones grew a little differently before you were born. This can cause a birthmark (like a wine stain), some bigger veins, and maybe one of your arms or legs is a bit bigger than the other. Doctors can help manage these things to make you feel better.

Signs & Symptoms

  • Port-wine stain (capillary malformation)
  • Varicose veins
  • Limb hypertrophy (overgrowth)
  • Venous malformations
  • Lymphatic malformations
  • Arteriovenous malformations (rare)
  • Pain
  • Swelling
  • Bleeding
  • Cellulitis
  • Deep vein thrombosis (DVT)
  • Pulmonary embolism (PE)
  • Discrepancy in limb length
  • Macrodactyly (enlarged digits)

Treatment Options

SUPPORTIVE

Compression therapy

MODERATELY EFFECTIVE
SURGERY FDA Approved

Sclerotherapy

MODERATELY EFFECTIVE
THERAPY FDA Approved

Laser therapy

MODERATELY EFFECTIVE
SURGERY

Surgery (e.g., vein stripping, epiphysiodesis)

MODERATELY EFFECTIVE
MEDICATION FDA Approved

Pain management (analgesics)

SUPPORTIVE
MEDICATION FDA Approved

Anticoagulation (e.g., heparin, warfarin, DOACs)

MODERATELY EFFECTIVE
THERAPY

Physical therapy

SUPPORTIVE
SUPPORTIVE

Custom orthotics and prosthetics

SUPPORTIVE
MEDICATION FDA Approved

Sirolimus (Rapamycin)

EXPERIMENTAL Approved 2009

Diagnosis

  • Clinical examination
  • Medical history
  • Doppler ultrasound
  • Magnetic resonance imaging (MRI)
  • Computed tomography angiography (CTA)
  • Venography
  • Lymphoscintigraphy
  • Genetic testing (limited utility, primarily for exclusion of other conditions)

History

Klippel-Trenaunay Syndrome was first described in 1900 by French physicians Maurice Klippel and Paul Trénaunay.

Recent Breakthroughs

2022

Sirolimus Shows Promise in Reducing Symptoms of Vascular Malformations

A study published in the *Journal of Vascular Anomalies* demonstrated that sirolimus (rapamycin) can significantly reduce the size and symptoms of vascular malformations in patients with KTS.

2023

Genetic Mosaicism Investigated in Klippel-Trenaunay Syndrome

Research is ongoing to identify the specific genetic mutations responsible for KTS, with a focus on mosaic mutations that occur during embryonic development. This may lead to more targeted therapies in the future.